{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:14:54Z","timestamp":1788261294986,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41433-025-03637-0","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T15:46:01Z","timestamp":1738597561000},"page":"1356-1363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world outcomes of Voretigene Neparvovec: a single-centre consecutive case series"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3820-137X","authenticated-orcid":false,"given":"Assad","family":"Jalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1191-4989","authenticated-orcid":false,"given":"Mariantonia","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrta","family":"Lippera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Parry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8727-6592","authenticated-orcid":false,"given":"Graeme C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Banderas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Ashworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sus","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2923-0972","authenticated-orcid":false,"given":"Tsveta","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"3637_CR1","unstructured":"FDA. LUXTURNA. FDA. 2022; Available from: http:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapyproducts\/luxturna."},{"key":"3637_CR2","unstructured":"Luxturna. European Medicines Agency. 2024. Available from: http:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/luxturna."},{"key":"3637_CR3","first-page":"4293","volume":"41","author":"DA Thompson","year":"2000","unstructured":"Thompson DA, Gy\u00fcr\u00fcs P, Fleischer LL, Bingham EL, McHenry CL, Apfelstedt-Sylla E, et al. Genetics and phenotypes of RPE65 mutations in inherited retinal degeneration. Invest Ophthalmol Vis Sci. 2000;41:4293\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3637_CR4","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.preteyeres.2010.04.002","volume":"29","author":"AV Cideciyan","year":"2010","unstructured":"Cideciyan AV. Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog Retin Eye Res. 2010;29:398\u2013427.","journal-title":"Prog Retin Eye Res"},{"key":"3637_CR5","unstructured":"National Institute for Health and Care Excellence. Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations. 2019. https:\/\/www.nice.org.uk\/guidance\/hst11."},{"key":"3637_CR6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849\u201360.","journal-title":"Lancet"},{"key":"3637_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","volume":"388","author":"J Bennett","year":"2016","unstructured":"Bennett J, Wellman J, Marshall KA, McCague S, Ashtari M, DiStefano-Pappas J, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet. 2016;388:661\u201372.","journal-title":"Lancet"},{"key":"3637_CR8","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","volume":"374","author":"AM Maguire","year":"2009","unstructured":"Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, et al. Age-dependent effects of RPE65 gene therapy for Leber\u2019s congenital amaurosis: a phase 1 doseescalation trial. Lancet. 2009;374:1597\u2013605.","journal-title":"Lancet"},{"key":"3637_CR9","doi-asserted-by":"publisher","unstructured":"Fischer MD, Simonelli F, Sahni J, Holz FG, Maier R, Fasser C, et al. PERCEIVE Study Group. Real-World Safety and Effectiveness of Voretigene Neparvovec: Results up to 2 Years from the Prospective, Registry-Based PERCEIVE Study. Biomolecules. 2024;14:122. https:\/\/doi.org\/10.3390\/biom14010122.","DOI":"10.3390\/biom14010122"},{"key":"3637_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.oret.2021.11.005","volume":"6","author":"JD Sengillo","year":"2022","unstructured":"Sengillo JD, Gregori NZ, Sisk RA, Weng CY, Berrocal AM, Davis JL, et al. Visual Acuity, Retinal Morphology, and Patients\u2019 Perceptions after Voretigene Neparovec-rzyl Therapy for RPE65-Associated Retinal Disease. Ophthalmol Retina. 2022;6:273\u201383.","journal-title":"Ophthalmol Retina"},{"key":"3637_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/opo.12775","volume":"41","author":"LJ Wood","year":"2021","unstructured":"Wood LJ, Jolly JK, Buckley TM, Josan AS, MacLaren RE. Low luminance visual acuity as a clinical measure and clinical trial outcome measure: a scoping review. Ophthalmic Physiol Opt. 2021;41:213\u201323. https:\/\/doi.org\/10.1111\/opo.12775.","journal-title":"Ophthalmic Physiol Opt"},{"key":"3637_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000503931","volume":"63","author":"AK Bittner","year":"2020","unstructured":"Bittner AK, Ferraz MC. Reliability of Mesopic Measures of Visual Acuity and Contrast Sensitivity and Their Correlation with Rod and Cone Function in Retinitis Pigmentosa. Ophthalmic Res. 2020;63:133\u201340. https:\/\/doi.org\/10.1159\/000503931.","journal-title":"Ophthalmic Res"},{"key":"3637_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ajo.2022.07.010","volume":"245","author":"WK Ngo","year":"2023","unstructured":"Ngo WK, Jenny LA, Kim AH, Kolesnikova M, Greenstein VC, Tsang SH. Correlations of FullField Stimulus Threshold With Functional and Anatomical Outcome Measurements in Advanced Retinitis Pigmentosa. Am J Ophthalmol. 2023;245:155\u201363. https:\/\/doi.org\/10.1016\/j.ajo.2022.07.010.","journal-title":"Am J Ophthalmol"},{"key":"3637_CR14","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00417-021-05508-2","volume":"260","author":"C Deng","year":"2022","unstructured":"Deng C, Zhao PY, Branham K, Schlegel D, Fahim AT, Jayasundera TK, et al. Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65associated Leber congenital amaurosis. Graefes Arch Clin Exp Ophthalmol. 2022;260:1543\u201350.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3637_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22180-6","volume":"12","author":"F Testa","year":"2022","unstructured":"Testa F, Melillo P, Di Iorio V, Iovino C, Farinaro F, Karali M, et al. Visual function and retinal changes after voretigene neparvovec treatment in children with biallelic RPE65related inherited retinal dystrophy. Sci Rep. 2022;12:17637.","journal-title":"Sci Rep"},{"key":"3637_CR16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/biom14010122","volume":"14","author":"MD Fischer","year":"2024","unstructured":"Fischer MD, Simonelli F, Sahni J, Holz FG, Maier R, Fasser C, et al. Real-World Safety and Effectiveness of Voretigene Neparvovec: Results up to 2 Years from the Prospective, Registry-Based PERCEIVE Study. Biomolecules. 2024;14:122.","journal-title":"Biomolecules"},{"key":"3637_CR17","doi-asserted-by":"crossref","unstructured":"Gerhardt MJ, Priglinger CS, Rudolph G, Hufendiek K, Framme C, J\u00e4gle H, et al. Gene Therapy with Voretigene Neparvovec Improves Vision and Partially Restores Electrophysiological Function in Pre-School Children with Leber Congenital Amaurosis. Biomedicines. 2022;11:103.","DOI":"10.3390\/biomedicines11010103"},{"key":"3637_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1167\/tvst.12.4.17","volume":"12","author":"CA Ku","year":"2023","unstructured":"Ku CA, Igelman AD, Huang SJ, Vasconcelos H, da Palma MM, Bailey ST, et al. Improved Rod Sensitivity as Assessed by Two-Color Dark-Adapted Perimetry in Patients With RPE65-Related Retinopathy Treated With Voretigene Neparvovec-rzyl. Transl Vis Sci Technol. 2023;12:17.","journal-title":"Transl Vis Sci Technol"},{"key":"3637_CR19","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.3390\/biom13101484","volume":"13","author":"P Kiraly","year":"2023","unstructured":"Kiraly P, Cottriall CL, Taylor LJ, Jolly JK, Cehajic-Kapetanovic J, Yusuf IH, et al. Outcomes and Adverse Effects of Voretigene Neparvovec Treatment for Biallelic RPE65-Mediated Inherited Retinal Dystrophies in a Cohort of Patients from a Single Center. Biomolecules. 2023;13:1484.","journal-title":"Biomolecules"},{"key":"3637_CR20","unstructured":"Lorenz B, K\u00fcnzel SH, Preising MN, Scholz JP, Chang P, Holz FG, et al. Single Center Experience with Voretigene Neparvovec Gene Augmentation Therapy in RPE65 Mutation\u2013Associated Inherited Retinal Degeneration in a Clinical Setting. Ophthalmology. 2023. Available from: http:\/\/www.aaojournal.org\/article\/S0161-6420(23)00631-0\/fulltext."},{"key":"3637_CR21","doi-asserted-by":"crossref","unstructured":"Maguire AM, Russell S, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials. Ophthalmology. 2019;126:1273\u201385.","DOI":"10.1016\/j.ophtha.2019.06.017"},{"key":"3637_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100975","volume":"86","author":"C Botto","year":"2022","unstructured":"Botto C, Rucli M, Tekinsoy MD, Pulman J, Sahel JA, Dalkara D. Early and late stage gene therapy interventions for inherited retinal degenerations. Prog Retin Eye Res. 2022;86:100975.","journal-title":"Prog Retin Eye Res"},{"key":"3637_CR23","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.ophtha.2022.06.018","volume":"129","author":"L Kessel","year":"2022","unstructured":"Kessel L, Christensen UC, Klemp K. Inflammation after Voretigene Neparvovec Administration in Patients with RPE65-Related Retinal Dystrophy. Ophthalmology. 2022;129:1287\u201393.","journal-title":"Ophthalmology"},{"key":"3637_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2023.101879","volume":"32","author":"AK Lidder","year":"2023","unstructured":"Lidder AK, Choi S, Modi YS, Brodie SE, Davis JL, Gregori NZ, et al. Bilateral exudative retinal detachments after subretinal gene therapy with voretigene neparvovec-rzyl for RPE65 Leber Congenital Amaurosis. Am J Ophthalmol Case Rep. 2023;32:101879.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"3637_CR25","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/s41433-022-02262-5","volume":"37","author":"A Jalil","year":"2023","unstructured":"Jalil A, Ivanova T, Moussa G, Parry NRA, Black GCM. Retinal gene therapy in RPE-65 gene mediated inherited retinal dystrophy. Eye. 2023;37:1874\u20137.","journal-title":"Eye"},{"key":"3637_CR26","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1136\/bjophthalmol-2021-321023","volume":"107","author":"FF Reichel","year":"2023","unstructured":"Reichel FF, Seitz I, Wozar F, Dimopoulos S, Jung R, Kempf M, et al. Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec. Br J Ophthalmol. 2023;107:1331\u20135.","journal-title":"Br J Ophthalmol"},{"key":"3637_CR27","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.ophtha.2023.02.015","volume":"130","author":"K Stingl","year":"2023","unstructured":"Stingl K, Stingl K, Schwartz H, Reid MW, Kempf M, Dimopoulos S, et al. Full-field Scotopic Threshold Improvement after Voretigene Neparvovec-rzyl Treatment Correlates with Chorioretinal Atrophy. Ophthalmology. 2023;130:764\u201370.","journal-title":"Ophthalmology"},{"key":"3637_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100915","volume":"83","author":"K Bucher","year":"2021","unstructured":"Bucher K, Rodr\u00edguez-Bocanegra E, Dauletbekov D, Fischer MD. Immune responses to retinal gene therapy using adeno-associated viral vectors - Implications for treatment success and safety. Prog Retin Eye Res. 2021;83:100915.","journal-title":"Prog Retin Eye Res"},{"key":"3637_CR29","doi-asserted-by":"publisher","first-page":"a041307","DOI":"10.1101\/cshperspect.a041307","volume":"13","author":"J Bennett","year":"2023","unstructured":"Bennett J, Maguire AM. Lessons Learned from the Development of the First FDAApproved Gene Therapy Drug, Voretigene Neparvovec-rzyl. Cold Spring Harb Perspect Med. 2023;13:a041307.","journal-title":"Cold Spring Harb Perspect Med"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03637-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03637-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03637-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T10:47:16Z","timestamp":1746010036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03637-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3637"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03637-0","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was a retrospective anonymized data collection, and hence had ethical approval exemption.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participation"}}]}}